Vestal Point Capital’s Exact Sciences EXAS Stock Holding History

Vestal Point Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-75,000	Closed	-$4.1M	–	92
2025 Q3	$4.1M	Sell	75,000 -625,000	-89%	-$31.2M	0.19%	66
2025 Q2	$37.2M	Buy	+700,000	New	+$35.6M	1.96%	17
2024 Q3	–	Sell	-925,000	Closed	-$39.1M	–	76
2024 Q2	$39.1M	Buy	925,000 +825,000	+825%	+$45.4M	2.91%	9
2024 Q1	$6.91M	Buy	+100,000	New	+$6.33M	0.57%	36

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Vestal Point Capital's EXAS Position: Q4 2025 in Review

Vestal Point Capital sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 75,000 shares — an estimated $4.1M sold.

Vestal Point Capital first reported a position in EXAS in Q1 2024 and held it in 4 quarters. The position peaked at $39.1M in Q2 2024. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.

Vestal Point Capital reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
Vestal Point Capital sold 75,000 Exact Sciences shares in Q4 2025, an estimated $4.1M.
Vestal Point Capital first reported a position in Exact Sciences in Q1 2024 and held it in 4 quarters.
Vestal Point Capital's Exact Sciences position peaked at $39.1M in Q2 2024.
711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.

Based on Vestal Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.